- Home
- CELC vs BUI Comparison
CELC vs BUI Comparison
Compare CELC & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- BUI
- Stock Information
- Founded
- CELC 2011
- BUI 2011
- Country
- CELC United States
- BUI United States
- Employees
- CELC N/A
- BUI N/A
- Industry
- CELC Medical Specialities
- BUI Trusts Except Educational Religious and Charitable
- Sector
- CELC Health Care
- BUI Finance
- Exchange
- CELC Nasdaq
- BUI Nasdaq
- Market Cap
- CELC 440.7M
- BUI 518.5M
- IPO Year
- CELC 2017
- BUI N/A
- Fundamental
- Price
- CELC $13.15
- BUI $23.09
- Analyst Decision
- CELC Strong Buy
- BUI
- Analyst Count
- CELC 6
- BUI 0
- Target Price
- CELC $30.17
- BUI N/A
- AVG Volume (30 Days)
- CELC 184.2K
- BUI 59.8K
- Earning Date
- CELC 03-26-2025
- BUI 01-01-0001
- Dividend Yield
- CELC N/A
- BUI 6.79%
- EPS Growth
- CELC N/A
- BUI N/A
- EPS
- CELC N/A
- BUI 2.75
- Revenue
- CELC N/A
- BUI N/A
- Revenue This Year
- CELC N/A
- BUI N/A
- Revenue Next Year
- CELC N/A
- BUI N/A
- P/E Ratio
- CELC N/A
- BUI $7.77
- Revenue Growth
- CELC N/A
- BUI N/A
- 52 Week Low
- CELC $10.35
- BUI $18.73
- 52 Week High
- CELC $22.19
- BUI $24.22
- Technical
- Relative Strength Index (RSI)
- CELC 60.85
- BUI 46.89
- Support Level
- CELC $12.55
- BUI $23.00
- Resistance Level
- CELC $13.25
- BUI $23.50
- Average True Range (ATR)
- CELC 0.68
- BUI 0.32
- MACD
- CELC 0.14
- BUI 0.02
- Stochastic Oscillator
- CELC 85.79
- BUI 38.06
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options.